Zeke Capital Advisors LLC acquired a new stake in STERIS plc (NYSE:STE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,218 shares of the medical equipment provider’s stock, valued at approximately $215,000.
Other large investors have also added to or reduced their stakes in the company. Raymond James Trust N.A. increased its holdings in STERIS by 4.0% in the 2nd quarter. Raymond James Trust N.A. now owns 2,002 shares of the medical equipment provider’s stock valued at $307,000 after acquiring an additional 77 shares during the last quarter. Parallel Advisors LLC increased its position in shares of STERIS by 5.0% during the second quarter. Parallel Advisors LLC now owns 1,433 shares of the medical equipment provider’s stock valued at $219,000 after acquiring an additional 68 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of STERIS by 16.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,058 shares of the medical equipment provider’s stock valued at $2,465,000 after acquiring an additional 2,218 shares during the last quarter. Symmetry Partners LLC increased its position in shares of STERIS by 24.7% during the second quarter. Symmetry Partners LLC now owns 2,149 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 426 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of STERIS by 41.5% in the second quarter. SG Americas Securities LLC now owns 9,112 shares of the medical equipment provider’s stock valued at $1,398,000 after purchasing an additional 2,674 shares during the period. Hedge funds and other institutional investors own 89.97% of the company’s stock.
STE has been the topic of a number of recent research reports. Stephens lifted their target price on shares of STERIS from $170.00 to $200.00 in a report on Wednesday, October 7th. Robert W. Baird boosted their target price on shares of STERIS from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. JMP Securities boosted their price objective on shares of STERIS from $180.00 to $200.00 in a research report on Thursday, October 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $189.50.
In other news, Director Richard C. Breeden sold 25,000 shares of STERIS stock in a transaction on Monday, August 24th. The shares were sold at an average price of $152.67, for a total transaction of $3,816,750.00. Following the transaction, the director now owns 31,681 shares in the company, valued at approximately $4,836,738.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John Adam Zangerle sold 2,000 shares of STERIS stock in a transaction on Monday, September 14th. The stock was sold at an average price of $167.00, for a total transaction of $334,000.00. The disclosure for this sale can be found here. Insiders sold 58,602 shares of company stock worth $9,783,141 in the last 90 days. 1.20% of the stock is currently owned by corporate insiders.
Shares of STE opened at $195.58 on Tuesday. The stock’s fifty day moving average is $183.25 and its 200-day moving average is $163.50. The firm has a market capitalization of $16.69 billion, a price-to-earnings ratio of 40.66 and a beta of 0.66. STERIS plc has a one year low of $105.69 and a one year high of $196.55. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.71 and a current ratio of 2.29.
STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, November 2nd. The medical equipment provider reported $1.48 EPS for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.21. STERIS had a return on equity of 16.24% and a net margin of 13.69%. The firm had revenue of $756.13 million during the quarter, compared to analyst estimates of $719.54 million. During the same period last year, the company posted $1.32 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Analysts forecast that STERIS plc will post 5.64 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Tuesday, November 24th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.82%. The ex-dividend date is Monday, November 23rd. STERIS’s dividend payout ratio is currently 28.37%.
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Story: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.